Introduction
Deposits of amyloid-b (Ab) peptides surrounded by dystrophic neurites (neuritic plaques) are a pathological hallmark of AD (Braak and Braak, 1991; Hardy and Selkoe, 2002) . Although several species of Ab peptides of 39-43 amino acids are produced in the brain (Glenner and Wong, 1984; Gouras et al., 1998; Masters et al., 1985) , Ab1-42 appears to be particularly critical in AD pathogenesis. Most mutations associated with autosomal dominant familial AD (FAD) increase the production or relative abundance of Ab1-42 (Tanzi and Bertram, 2005) . In transgenic mice that overexpress hAPP and develop age-dependent plaque deposition, the relative abundance of Ab1-42 correlated with amyloid deposition and with plaque-independent neuronal and synaptic deficits (Mucke et al., 2000; Palop et al., 2003) .
In general, Ab levels are determined by the balance between Ab production and removal, and defects in the proteolytic degradation of Ab peptides could contribute to AD, especially late-onset sporadic AD (Selkoe, 2001 ). Ab clearance involves several Ab-degrading enzymes, including insulin-degrading enzyme (IDE), neprilysin (NEP), endothelin-converting enzyme (ECE), plasmin, matrix metalloproteinase-9 (MMP-9), and indirectly, thimet oligopeptidase (Eckman et al., 2001; Iwata et al., 2001; Qiu et al., 1998; Tucker et al., 2000; Yamin et al., 1999; Yan et al., 2006) . Chronic transgenic overexpression of IDE or NEP in AD-related animal models markedly decreased the levels of Ab1-42 and Ab1-x, establishing the importance of those enzymes in regulating Ab turnover in vivo (Leissring et al., 2003) . Lentiviral overexpression of NEP in the brain decreased Ab deposits and associated neuropathology in adult hAPP transgenic mice with significant plaque loads (Marr et al., 2003) . The pronounced reductions in cerebral Ab levels in APP/presenilin transgenic mice housed in an enriched environment were associated with elevated levels of NEP (Lazarov et al., 2005) . These results suggest that the activation of Ab degradation and clearance is a promising therapeutic approach. Thus, understanding how levels of Ab, especially Ab1-42, are regulated by proteolysis has significant implications for both the pathogenesis and the treatment of AD.
Cathepsin B (CatB) (EC 3.4.22.1), a cysteine protease of the papain superfamily, degrades peptides and proteins that enter the endolysosomal system by endocytosis or phagocytosis (Chapman et al., 1997) . Enzymatically active CatB is secreted through exocytosis (Linebaugh et al., 1999) and degrades extracellular matrix in pathological conditions, including cancer and rheumatoid arthritis (Buck et al., 1992; Hashimoto et al., 2001) . In AD brains, neuronal CatB is localized in most early endosomes, a site of internalization and processing of APP to form Ab (Cataldo et al., 1997; Cataldo and Nixon, 1990) . Extracellular CatB is associated with amyloid plaques (Cataldo et al., 1997; Cataldo and Nixon, 1990) . CatB also colocalizes with both Ab1-40 and Ab1-42 in regulated secretory vesicles in chromaffin cells (Hook et al., 2005) .
Despite the close association of CatB with intracellular and extracellular Ab, the exact roles of CatB in APP processing and Ab metabolism in the central nervous system remain to be defined. It was suspected that CatB might cleave APP and contribute to Ab generation, exacerbating neuronal deficits in AD (Cataldo et al., 1997; Cataldo and Nixon, 1990; Hook et al., 2005; Mackay et al., 1997) . On the other hand, CatB may catalyze the cleavage of Ab peptides, resulting in Ab degradation and neuroprotection. Here we demonstrate that CatB reduces the relative abundance of Ab1-42 through limited proteolysis, suggesting that activation of CatB could offer a therapeutic strategy for AD.
Results

Genetic Ablation of CatB Increases Plaque Deposition and Neuropathology in hAPP Mice
To determine the role of CatB in APP processing and Ab metabolism in vivo, we crossed CatB 2/2 mice with hAPP mice that produce high levels of Ab in neurons. CatB activity was undetectable in CatB 2/2 mice and reduced to 50% of wild-type levels in heterozygotes (CatB +/2 ) ( Figure S1 in the Supplemental Data available with this article online). Western blot analyses with an antihAPP antibody (CT-15) revealed that CatB ablation in hAPP mice did not affect levels of C-terminal fragments (CTF) of hAPP, including a-CTF, b-CTF, or full-length hAPP (FL-hAPP) ( Figure 1A ). Levels of a-sAPP, detected with 6E10 antibody , were not affected by CatB ablation either ( Figure 1A ). These results suggest that CatB does not significantly affect the processing of hAPP.
Interestingly, hippocampal plaque loads were significantly higher in hAPP/CatB 2/2 mice than hAPP/CatB +/+ mice at 6 months of age, as shown by immunostaining with an anti-Ab antibody, 3D6 ( Figures 1B and 1C ). The number of neuritic plaques labeled with thioflavin S was also significantly higher in hippocampi of hAPP/ CatB 2/2 mice than in hAPP/CatB +/+ mice ( Figure 1D ). In addition, more amyloid deposits were detected in the cortex of hAPP/CatB 2/2 mice than in hAPP/CatB +/+ mice ( Figure 1E ). These results indicate that CatB is involved in reducing Ab deposition. Using an ELISA assay for human Ab, we next examined the effects of CatB ablation on hippocampal Ab1-42 and Ab1-x (approximates total Ab) levels. Although the increase in the absolute levels of Ab1-42 and Ab1-x in hAPP/CatB 2/2 mice did not reach statistical significance ( Figure S2 ), Ab1-42/ Ab1-x ratios were significantly higher in hAPP/CatB 2/2 mice than hAPP/CatB +/+ mice at 6-7 months of age ( Figure 1F ). This result is consistent with the increased plaque deposition in 6-to 7-month-old hAPP/CatB 2/2 mice. In 3-to 4-month-old hAPP mice before plaque deposition, ablation of CatB did not affect the absolute Ab1-42 or Ab1-x levels or the relative abundance of Ab1-42 ( Figure S2 ), suggesting that CatB exerts its antiamyloidogenic effects during or after the formation of plaques.
Learning deficits in hAPP mice are influenced by Ab1-42 levels and, on an inbred C57BL/6 background, correlated strongly with the depletion of the calcium binding protein calbindin-D28k in granule cells of the dentate gyrus (Palop et al., 2003 . Consistent with their increased levels of Ab1-42, 6-to 7-month-old hAPP/ CatB 2/2 mice had significantly lower calbindin levels in the dentate gyrus than age-matched hAPP/CatB +/+ mice ( Figures 1G and 1H ). +/+ and APP/CatB 2/2 mice (n = 9-10/genotype). Levels of hAPP fragments were normalized to those of GAPDH. (B) Photomicrographs of 3D6 immunostaining in the hippocampus of 6-to 7-month-old hAPP/CatB +/+ and hAPP/CatB 2/2 mice. Scale bar, 400 mm. (C and D) Genetic ablation of CatB increased plaque load in hippocampus (n = 10-12/genotype; *p < 0.05, unpaired Student's t test). The amount of Ab deposits was calculated as the percent area of the hippocampus covered by 3D6-immunoreactive material (C). Thioflavin S-positive neuritic plaques of the entire hippocampus region were counted in seven sections and graphed as average plaque number per section (D). (E) APP/CatB 2/2 mice have more 3D6-immunoreactive plaques in the cortex than APP/CatB +/+ mice. Plaques of the entire cortical region were counted in seven sections and graphed as average plaque number per section (n = 10-12/genotype; *p < 0.05, unpaired Student's t test). (F) ELISA measurements of hippocampal levels of Ab1-42 and Ab1-x (approximates total Ab). Ablating CatB increased Ab1-42/ Ab1-x ratios in 6-to 7-month-old mice (n = 10-12 mice/genotype; *p < 0.05, unpaired Student's t test). (G) Photomicrographs of calbindin immunostaining in the hippocampus of 6-to 7-month-old hAPP/CatB +/+ mice, hAPP/CatB 2/2 mice, and littermate controls that do not express human hAPP (CatB +/+ and CatB 2/2 ). Scale bar, 400 mm. (H) Calbindin levels in the dentate gyrus relative to those in the CA1 regions were significantly lower in hAPP/CatB 2/2 mice than in hAPP/CatB +/+ mice and littermate controls (CatB +/+ and CatB 2/2 ) (n = 10-12/genotype; ***p < 0.001, Tukey Kramer post hoc test). Error bars represent means 6 SEM (A, C-F, and H).
These results suggest that CatB reduces plaque deposition and relative Ab1-42 levels and protects neurons against the Ab-induced depletion of synaptic activitydependent proteins.
CatB Accumulates Preferentially within Neuritic Plaques in hAPP Mice
To understand the mechanisms underlying the antiamyloidogenic and neuroprotective effects of CatB, we characterized the association of CatB with amyloid plaques in 16-to 20-month-old hAPP mice. Brain sections from hAPP mice were colabeled with a CatB-specific antibody and with either 3D6, which stains both mature and diffuse Ab deposits, or thioflavin S, which labels the b sheet structures in mature plaques (Figure 2A) . CatB was present in a subpopulation of 3D6-positive deposits ( Figure 2A ) and thioflavin S-positive plaques ( Figure 2A ). More thioflavin S-positive than 3D6-positive deposits were immunoreactive for CatB, indicating that CatB accumulates preferentially in mature plaques ( Figure 2B ). Anti-CatB immunostaining of brain sections from hAPP/CatB 2/2 mice yielded no fluorescent signal in 3D6-positive plaques or NeuN-positive neurons, confirming the specificity of CatB antibody ( Figure S3) . Notably, in 6-to 7-month-old hAPP/CatB +/+ mice, CatB was present in most of the amyloid plaques ( Figure S4 ), consistent with the plaque-reducing effect of CatB in hAPP mice at this age ( Figures 1B-1E) .
Within neuritic plaques, CatB immunoreactivity overlapped with dystrophic neurites labeled with an antihAPP antibody (8E5) (Cheng et al., 2004) (Figure 2C ). These CatB-positive amyloid plaques were also associated with clusters of reactive astroglia labeled with GFAP antibody (Figure 2D ), as well as microglia, as shown by crossing hAPP mice with CX3CR1 +/GFP mice, in which microglia are labeled with GFP ( Figure 2E ). Interestingly, CatB activity was present in the supernatants of primary cultures enriched for neurons, astrocytes, or microglia; the highest levels were detected in microglial cultures ( Figure S5 ). These results suggest that extracellular CatB accumulating within neuritic plaques could be produced by all three cell types, including activated microglia surrounding the plaques.
CatB in hippocampal CA1 pyramidal neurons of hAPP mice colocalized with lysosomal membrane glycoprotein 1 (LAMP1), a lysosomal marker ( Figure 2F ). CatB also colocalized with endosome-associated autoantigen 1 (EEA-1)-positive early endosomes, a site involved in APP processing and Ab generation ( Figure 2F ). The accumulation of CatB in early endosomes in neurons of vulnerable regions of hAPP brains is consistent with a role of neuronal CatB in modulating Ab levels. 
CatB Reduces Ab Levels in Primary Neurons
To investigate whether CatB directly affects Ab levels in neurons, we transduced primary cortical neurons from CatB 2/2 mice and CatB +/+ littermate controls with an adenoviral vector expressing hAPP. Ab1-42 levels were significantly higher in the supernatants from CatB 2/2 neurons than CatB +/+ neurons ( Figure 3A ). Lack of CatB did not increase Ab1-x levels in these cultures significantly ( Figure 3B ).
In complementary experiments, we inhibited CatB expression in primary cortical neuronal cultures from hAPP mice with a lentiviral vector encoding a small hairpin RNA targeting CatB (Lenti-shCatB) ( Figure 3C ). CatB activity was significantly lower in cultures expressing Lenti-shCatB than in cultures expressing a scrambled shRNA (Lenti-shSCR) ( Figure 3D ). Inhibiting CatB significantly increased Ab1-42 levels, suggesting that CatB negatively regulates Ab1-42 levels ( Figure 3E ). Ab1-x levels were also significantly elevated in cultures infected with Lenti-shCatB, indicating that CatB also reduces total Ab levels ( Figure 3F ).
To further confirm the effects of CatB on Ab levels, we increased CatB activity in primary neuronal cultures from hAPP mice with a lentiviral vector encoding mouse CatB cDNA (Lenti-CatB). Infection with Lenti-CatB resulted in significant increase in CatB activity ( Figure 3G ). Both Ab1-42 and Ab1-x levels were significantly reduced in cultures overexpressing CatB ( Figures 3H and 3I ).
CatB Is Increased in Ab1-42-Treated Neuronal Cells and in Brains of hAPP Mice
Our results so far demonstrate that levels of Ab, including Ab1-42, are downregulated by CatB in hAPP mice and primary neuronal cultures. Notably, elevated levels of Ab1-42 stimulate microglia to express more CatB mRNA . To determine if Ab1-42 also regulates CatB in neuronal cells, where the majority of Ab is made, we stimulated neuroblastoma (N2A) cells with increasing amounts of Ab1-42 and Ab1-40. Both CatB mRNA levels ( Figure 4A ) and enzymatic activities ( Figure 4B ) were markedly increased by Ab1-42; Ab1-40 had little or no effect. Treatment with preaggregated Ab1-40, however, induced a modest but significant increase in CatB activity, supporting the notion that 
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Levels of human Ab1-x and Ab1-42 in the supernatants were determined with an Ab ELISA and normalized to the protein concentrations in the cell lysates. Error bars represent means 6 SEM (A-B and D-I). n refers to number of samples per condition. (A and B) Levels of Ab1-42 (A) and Ab1-x (B) in CatB 2/2 (n = 6) and CatB +/+ neurons (n = 8) infected with hAPP adenovirus. *p < 0.05, Mann-Whitney U test. (C-F) Inhibition of CatB increased Ab levels in hAPP primary neurons. Diagram (not to scale) of the lentiviral vector Lenti-shCatB, which expresses both EGFP and shCatB (C). CatB activities (D) were significantly lower in hAPP neurons infected with Lenti-shCatB than in those infected with the control lentiviral vector expressing scrambled shRNA (Lenti-shSCR) (n = 15; ***p < 0.001, unpaired Student's t test). Levels of Ab1-42 (E) and Ab1-x (F) were significantly higher in cultures infected with Lenti-shCatB than in those infected with Lenti-shSCR (n = 15; *p < 0.05, unpaired Student's t test). Average Ab levels in LentishSCR-infected cultures were arbitrarily set as 1. (G-I) Overexpression of CatB decreased Ab levels in hAPP primary neurons. CatB activities (G) were significantly increased in hAPP neurons infected with Lenti-CatB (n = 4, ***p < 0.001, unpaired Student's t test). Levels of Ab1-42 (H) and Ab1-x (I) were significantly lower in cultures infected with Lenti-CatB than in those infected with equal amounts of Lenti-control (n = 4; *p < 0.05, unpaired Student's t test). Average Ab levels in Lenti-control-infected cultures were arbitrarily set as 1.
regulation of CatB is influenced by the assembly states of Ab peptides ( Figure 4C ).
To determine if Ab levels modulate CatB activities in vivo, we compared the enzymatic activities of CatB in the hippocampus of hAPP mice. Compared with age-matched nontransgenic controls, CatB levels were higher in hAPP mice both before (1-3 months) and after (7-8 months) plaque deposition ( Figure 4D ), suggesting that the hAPP/Ab-induced increase in CatB activities does not depend on insoluble Ab deposits in vivo. At 16-20 months, CatB activities were similar to those in nontransgenic controls, indicating that hAPP/ Ab failed to stimulate CatB at old age ( Figure 4D ).
CatB Mediates C-Terminal Truncations of Ab1-42 In Vitro
Since the relative abundance of Ab1-42 was increased in the hippocampus of hAPP/CatB 2/2 mice and in CatB 2/2 neurons overexpressing hAPP, we hypothesized that Ab1-42 is a substrate for CatB and that CatB reduces levels of Ab1-42 through proteolytic cleavage. Under cell-free conditions, synthetic Ab1-42 was incubated with purified CatB at pH 6.0, a pH close to that of endosomes, where CatB is likely to encounter Ab intracellularly (Cataldo et al., 1997; Hook et al., 2002) ( Figure 1F ). The proteolytic products were analyzed with SELDI-TOF mass spectrometry. Incubating Ab1-42 with CatB resulted in the dose-dependent generation of Ab1-40, Ab1-38, and Ab1-33 through proteolytic cleavage at Val 40 -Ile 41 , Gly 38 -Gly 39 , and Gly 33 -Leu 34 ( Figure 5A ). No truncations occurred in the presence of the inhibitor CA074 or in the absence of CatB, confirming that the truncations were dependent on the proteolytic activity of CatB. Increasing the concentration of CatB decreased Ab1-42 and increased Ab1-38 (Figures 5A).
The dose-dependent cleavage of Ab1-42 was confirmed by western blot analysis of acid-urea gels ( Figure 5B ). Levels of Ab1-40 were increased initially at lower doses (100-400 ng/ml), but decreased at higher doses (0.4-2.5 mg/ml) ( Figure 5A ). These results indicate that CatB acts as a carboxydipeptidase that cleaves Ab1-42 at the C terminus to generate Ab1-40, which in turn serves as a substrate for the generation of Ab1-38. Although CatB did not appear to completely degrade Ab peptides, Ab1-33 was also generated (Figures 5A and 5D) in a dose-dependent manner, presumably by endopeptidase activity. Consistent with the weaker endopeptidase than carboxydipeptidase activity of CatB at acidic pH (4.0-6.0) (Musil et al., 1991; Nagler et al., 1997) , higher concentrations of CatB were required to generate Ab1-33 than to generate Ab1-40 and Ab1-38 ( Figure 5A ). Interestingly, even when Ab1-40 was almost completely converted to Ab1-38, no Ab1-36 was generated from Ab1-38 ( Figure S6 ), indicating that Ab1-38 is not a substrate for CatB's carboxydipeptidic activity. Thus, CatB may counteract amyloidosis by catalyzing the sequence-specific C-terminal truncation of Ab1-42.
CatB Cleaves Aggregated Ab1-42 and Reduces Levels of Ab Fibrils In Vitro Next, we investigated whether CatB also cleaves soluble and insoluble Ab1-42 assemblies. The assembly state of Ab1-42 was confirmed with negative-staining electron microscopy ( Figure 5C ). Nonfibrillar Ab1-42 assemblies were highly toxic in cultured primary neurons (Chen et al., 2005; Hartley et al., 1999) and, at pH 6.0, were cleaved by CatB as efficiently as nonaggregated preparations, resulting in the same C-terminally truncated peptides, Ab1-40, Ab1-38, and Ab1-33 ( Figure 5D ), which are less toxic and fibrillogenic than Ab1-42 (Iijima et al., 2004; Zhang et al., 2002) . Incubation of CatB induced a marked decrease in the amounts of high-molecular (D) CatB activity levels were significantly higher in young (1-3 months) and middleaged (7-8 months), but not elderly (16-20 months), hAPP mice, than in age-matched nontransgenic (ntg) controls. Error bars represent means 6 SEM (n = 8-18 mice/genotype; *p < 0.05; **p < 0.01, Tukey Kramer post hoc test).
weight (MW) Ab assemblies, as shown on Tricine SDS-PAGE gels. Levels of low-MW Ab1-42 oligomers and monomers, detected with an antibody specific for Ab1-42, were also reduced. Inclusion of the CatB inhibitor CA074 significantly diminished such effects ( Figure 5E ). These results suggest that CatB effectively targets Ab assemblies in vitro.
At neutral pH (w7.0), the ability of CatB to cleave Ab, especially nonaggregated (fresh) Ab, was markedly reduced ( Figure 5F ). Nevertheless, nonfibrillar and fibrillar Ab assemblies were cleaved by CatB even at neutral pH, resulting in the same truncated Ab species observed at pH 6.0 (Figures 5A and 5F ). The ability of CatB to cleave even aggregated Ab1-42 suggested that CatB might be able to reduce preformed Ab fibrils. Indeed, incubation of fibrillar Ab1-42 with CatB did reduce the amount of fibrillar structures ( Figure 5G ). This effect depended on the proteolytic activity of CatB, as demonstrated by inhibition with CA074 ( Figure 5G ).
CatB Gene Transfer Reduces Amyloid Plaques in Aged hAPP Mice
The ability of CatB to cleave Ab1-42 aggregates and the accumulation of CatB within amyloid plaques support the notion that CatB might reduce established plaques in aged hAPP mice. To test this hypothesis, we injected Lenti-CatB, the vector we used to increase CatB levels in primary neuronal cultures ( Figure 3G ), into the hippocampus of 12-to 15-month-old hAPP mice, which have significant plaque deposition. Lenti-control, which does not encode a functional protein, served as a negative control for nonspecific viral effects. A lentiviral vector overexpressing NEP (Lenti-NEP) (Marr et al., 2003) served as a positive control. Three weeks after the stereotaxic injections, CatB immunoreactivity ( Figure 6A ) and enzymatic activity ( Figure 6B ) were much stronger in the injected hippocampus, especially in the dentate gyrus, than those in the contralateral side. Lenti-NEP also induced higher NEP immunoreactivity in the dentate gyrus (data not shown).
Injection of Lenti-CatB ( Figure 6C ) or Lenti-NEP significantly reduced 3D6-postive Ab deposits in the ipsilateral dentate gyrus; control virus had no effect ( Figure  6D ). These results suggest that, in aged hAPP mice, CatB reduces preexisting plaque load as effectively as NEP. Notably, CatB gene transfer markedly reduced thioflavin S-positive neuritic plaques ( Figures 6E and  6F ), whereas Lenti-NEP did not ( Figure 6F ). Thus, CatB was more effective than NEP in removing aggregated Ab in mature amyloid plaques.
Discussion
Our study demonstrates that CatB exerts antiamyloidogenic and neuroprotective effects in vivo, most likely through C-terminal proteolytic truncation of Ab1-42. CatB has been implicated in AD because of its prominent association with neuritic plaques and enlarged endosomes in AD brains (Cataldo et al., 1997 (Cataldo et al., , 2004 Cataldo and Nixon, 1990; Hook et al., 2005; Mackay et al., 1997) . However, these studies postulated that CatB might contribute to Ab generation through proteolysis of APP. We directly tested this hypothesis and discovered that CatB ablation had no effect on APP Reduction of 3D6-immunoreactive Ab deposits in the hippocampus of 12-to 15-month-old hAPP mice after injection of Lenti-CatB (10 mice) or Lenti-NEP (7 mice), but not Lenti-Control (5 mice). For each mouse, the extent of hippocampal Ab deposits was expressed as the ratio between the percent area occupied by 3D6 immunoreactivity on the injected versus uninjected side. *p < 0.05, Tukey Kramer post hoc test. (E) Representative photomicrograph of thioflavin S staining of the Lenti-CatB-injected (left) and uninjected (right) hippocampus in a 12-to 15-month-old hAPP mouse. (F) Reduction of thioflavin S-positive plaques in the hippocampus of 12-to 15-monthold hAPP mice after injection of Lenti-CatB (10 mice), but not Lenti-NEP (7 mice) or Lenti-Control (5 mice). For each mouse, the extent of hippocampal plaques was expressed as the ratio of the percent area of thioflavin S-positive plaques on the injected versus uninjected side. *p < 0.05, Tukey Kramer post hoc test.
processing. In fact, CatB inhibition increased Ab levels and plaque deposition. Moreover, CatB cleaved fibrillar as well as nonfibrillar assemblies of Ab1-42 into shorter Ab peptides that are less pathogenic and amyloidogenic. Thus, this function of CatB should counteract both plaque-dependent and plaque-independent neuronal deficits.
Consistent with this notion, reducing CatB activity in hAPP mice augmented the neuritic plaque burden and depleted neuronal calbindin levels in the dentate gyrus. Calbindin reductions in the dentate gyrus of hAPP mice correlate tightly with Ab-dependent deficits in learning and memory (Palop et al., 2003) . While hAPP/Ab expression was sufficient to deplete calbindin in the dentate gyrus of inbred C57BL/6 mice Palop et al., 2003 Palop et al., , 2005 , CatB ablation was required to elicit this molecular alteration in the hAPP mice analyzed here, which were on a C57BL/6 3 129 hybrid background. The relative resistance to calbindin depletion in hAPP mice on a hybrid background likely reflects heterosis, or hybrid vigor, a well-documented phenomenon in plants and mammals (Comings and MacMurray, 2000) .
Interestingly, the proteolytic activities of CatB were stimulated by high levels of Ab1-42 in young and middle-aged, but not old, hAPP mice. Thus, upregulation of CatB may represent a protective mechanism that fails with aging. Aging also reduces the levels of somatostatin, resulting in markedly decreased NEP levels in vulnerable regions of the aging brain (Iwata et al., 2004; Saito et al., 2005) . Together, these studies provide evidence that aging-dependent defects in Ab catabolism by proteolysis may underlie Ab accumulation in late-onset sporadic AD.
Within the lysosomal cysteine protease family, CatB possesses the unique ability to act both as a dipeptidyl carboxypeptidase and an endopeptidase. Because it has two histidine residues (His110 and His111) in a 20 residue occluding loop on the primer side of its catalytic site, CatB has greater carboxydipeptidic than endopeptidic activity (Illy et al., 1997; Khouri et al., 1991; Nagler et al., 1997) . Both proteolytic activities appear to be involved in the CatB-dependent C-terminal truncation of Ab1-42. Dipeptidyl carboxypeptidase activity would be expected to lead to sequential conversion of Ab1-42 into Ab1-40 and Ab1-38, whereas Ab1-33 appears to be the only fragment generated through endopeptidic cleavage.
The generation of distinct C-terminally truncated Ab fragments by CatB offers a unique mechanism to modulate the levels of Ab, especially Ab1-42. Interestingly, CatB also catalyzes C-terminal truncations of epidermal growth factor and insulin-like growth factor, leading to the negative regulation of their signaling (Authier et al., 1999; Tsujinaka et al., 1995) . Since Ab oligomers have been shown to inhibit neurotransmission and synaptic plasticity (Cleary et al., 2005; Walsh et al., 2002; Walsh and Selkoe, 2004) , CatB might affect the activity in neuronal circuits by modulating the levels of different Ab assemblies. Thus, CatB may fulfill important regulatory functions through limited proteolysis under both physiological and pathophysiological conditions.
The mechanisms that underlie CatB's cleavage of aggregated Ab preparations are not well understood. Few enzymes efficiently degrade highly aggregated Ab peptides. Naturally occurring Ab dimers and trimers are resistant to IDE in the culture medium, suggesting that IDE cannot effectively degrade oligomeric Ab (Qiu et al., 1998; Vekrellis et al., 2000) . Although NEP is capable of degrading oligomeric Ab peptides (Kanemitsu et al., 2003; Huang et al., 2006) , we were unable to find evidence in the literature that it efficiently degrades protofibrillar and fibrillar Ab. Plasmin degrades fibrillar Ab with a proteolytic efficiency that is only about 1% of that for freshly dissolved (i.e., largely monomeric) Ab (Tucker et al., 2000) . Recently, MMP-9 was found to degrade Ab fibrils in vitro (Yan et al., 2006) . It is likely that IDE, NEP, plasmin, MMP-9, and CatB target different forms of Ab, collaborating to effectively remove Ab and prevent AD. In primary neurons from hAPP mice, CatB reduces levels of both Ab1-42 and total Ab, suggesting that CatB could facilitate complete degradation of Ab peptides by generating C-terminally truncated Ab peptides that are less prone to aggregation and thus are degraded more easily by other proteases, such as NEP and IDE.
Ablation of CatB increased the relative abundance of Ab1-42 in purified primary neuronal cultures containing <5% of glia but not in 3-to 4-month-old mice. Conceivably, alternative Ab-degrading activities of astrocytes and microglia (Wyss-Coray et al., 2001; Koistinaho et al., 2004) may have compensated for the lack of CatB in vivo. However, CatB exerted robust antiamyloidogenic effects in 6-to 7-month-old mice, suggesting a predominant effect on Ab during or after plaque formation. Our finding that CatB gene transfer effectively cleared preformed plaques in 12-to 15-month-old hAPP mice further supports this conclusion. Indeed, CatB was more effective than NEP in reducing thioflavin S-positive neuritic plaques, likely due to CatB's ability to target aggregated Ab and its accumulation within neuritic plaques. These results reinforce the notion that CatB and NEP contribute to overall Ab degradation in the brain by targeting different forms of Ab, reflecting their distinct proteolytic properties and subcellular localizations.
Accumulating evidence supports the notion that Ab oligomers, but not Ab plaques, are critical in mediating synaptic and cognitive deficits in hAPP mice (Cleary et al., 2005; Hsia et al., 1999; Lesne et al., 2006; Mucke et al., 2000; Walsh et al., 2002) . Although CatB efficiently reduces oligomeric Ab1-42 in vitro, it is not yet known whether the overexpression of CatB also reduces levels of toxic Ab oligomers in vivo. CatB could directly reduce the local concentration of Ab1-42 oligomers through proteolytic cleavage of monomers and oligomers. On the other hand, the cleavage of highly fibrillogenic Ab1-42 could facilitate dissociation of fibrils, resulting in an increase in the local oligomer concentration, and thus be harmful. Further studies are required to determine the effects of CatB overexpression on Ab oligomers and associated neuronal deficits in hAPP mice.
CatB has the potential to act intracellularly and extracellularly, as well as in diverse cell types. Therefore, it could help remove Ab from the extracellular milieu or attenuate intracellular Ab toxicity, which has been asso- (Frautschy et al., 1998) . Since microglia express higher levels of CatB than other cell types, CatB might also promote microglia-mediated Ab clearance by cleaving Ab aggregates internalized through phagocytosis.
Independent of the specific sites in which CatB launches its most critical attack on Ab1-42, our findings suggest that inhibition or loss of CatB activity could interfere with its protective function and promote the development of AD, whereas increasing CatB activity could counteract Ab accumulation and aggregation, offering a potential approach to the treatment of AD.
Experimental Procedures
Mice CatB 2/2 mice (129sv) obtained from Dr. Hidde Ploegh (Harvard Medical School, Boston, MA) (Deussing et al., 1998) were crossed with hAPP mice (C57BL/6J) from line J20 (Mucke et al., 2000) . The first cross resulted in hAPP/CatB +/2 mice, which were crossed with CatB +/2 (CatB heterozygotes that do not express hAPP) to generate six genotypes: hAPP/CatB , and CatB +/2 . PCR-based genotyping was performed as described (Deussing et al., 1998; Mucke et al., 2000) . We have also generated hAPP/CX3CR1 +/GFP mice, which express green fluorescent protein (GFP) in microglia that retain normal fractalkine receptor function (Jung et al., 2000) by crossing hAPP mice with CX3CR1 2/2 mice with targeted GFP insertion (Dr. D Littman, New York University School of Medicine, New York, NY). All measurements were performed on gender-balanced groups. Anesthetized mice were flush perfused transcardially with PBS. One hemibrain was fixed in 4% phosphate-buffered paraformaldehyde at 4 C for 48 hr, and the other was stored at 270 C. All experiments were approved by the Committee on Animal Research of the University of California, San Francisco (UCSF).
Immunohistochemistry and Quantitation of Immunoreactive Structures
Sliding microtome sections (30 mm) were prepared for immunohistochemistry. For fluorescence double-labeling, sections were incubated first with rabbit anti-CatB (1:1000, Upstate Biotechnology, Lake Placid, NY), mouse anti-EEA1 (1:50, BD Biosciences, Franklin Lakes, NJ), mouse mAb anti-Ab (1:500, 3D6, Elan Pharmaceuticals, South San Francisco, CA), mouse anti-APP (8E5, 1:1000, Elan Pharmaceuticals), anti-NeuN (1:1000 Chemicon, Temecula, CA), or rabbit anti-GFAP (1:1000, Sigma, St. Louis, MO), and then with fluoresceinlabeled donkey anti-rabbit (1:300, Jackson ImmunoResearch, West Grove, PA) and Texas red-labeled donkey anti-mouse (1:300, Jackson ImmunoResearch). Microglia were labeled with GFP in the heterozygous CX3CR1 +/GFP mice (Jung et al., 2000) that express or do not express hAPP. Amyloid plaques were stained with thioflavin S. High-power immunofluorescence images were obtained by confocal microscopy (Radiance 2000, BioRad, Hercules, CA). Lower-power digitized images were acquired with a BX-60 microscope (Olympus, Melville, NY) and Axiovision software (Carl Zeiss, Germany). Areas of fluorescent signal were quantified with ImageJ software (NIH Image). The proportion of CatB-immunoreactive plaques was calculated by dividing the areas occupied by both CatB and either 3D6 or thioflavin S by the area occupied by 3D6 or thioflavin S alone.
Calbindin expression in the dentate gyrus and plaque loads in the hippocampus were quantified as described (Palop et al., 2003) . After endogenous peroxidase activity was quenched, sections were incubated with rabbit anti-calbindin (1:15,000, Swant, Bellinzona, Switzerland), biotinylated goat anti-rabbit (1:200, Vector Laboratories, Burlingame, CA), or biotinylated mouse monoclonal antibody 3D6 (5 mg/ml, Elan). Binding of the antibody was detected with the Elite kit (Vector Laboratories) using diaminobenzidine and H 2 O 2 for development. Images were obtained with a DEI-470 digital camera (Optronics, Goleta, CA). The integrated optical density from three coronal sections was determined with a Bioquant image analysis system and averaged in two areas of the molecular layer of the dentate gyrus and of the stratum radiatum of the CA-1 region, in which calbindin levels remained stable. Calbindin levels were expressed as the ratio of integrated optical density in the molecular layer and in the stratum radiatum of the CA1. The plaque load was calculated as the percent area of the hippocampus covered by 3D6-immunoreactive material. Three coronal sections were analyzed per mouse, and the average of the individual measurements was used to calculate group means.
Cell Culture and Lentiviral/Adenoviral Infection Unless otherwise noted, all cell culture supplies, medium, and antibiotics were from Invitrogen (Carlsbad, CA). The murine neuronal cell line N2A was maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin G, and 100 mg/ml streptomycin at 37 C in a humidified atmosphere containing 5% CO 2 . Before treatment, the medium was replaced with Neurobasal A medium supplemented with N2, and the cells were treated with fresh Ab1-42 or Ab1-40 at various concentrations for 24 hr.
For primary neuronal cultures, cortices from mouse pups of different genotypes were isolated on postnatal day 0 or 1. Dissociated cells were plated at 800,000 cells/ml in Neurobasal A medium supplemented with B27, 100 U/ml penicillin G, and 100 mg/ml streptomycin. The genotypes of individual cultures were determined by PCR analysis of the tails of the pups from which the cells were obtained.
Expression of CatB in APP-FAD neurons (hAPP) was inhibited by overexpressing shRNA, which targets endogenous mouse CatB under the U6 promoter. The target sequence was 5 0 -GAAGCTGTG TGGCACTGTC-3 0 . The U6-shRNA expression cassette (pSilencer 1.0, Ambion, Austin, TX) was inserted between the PacI and the NheI sites of a modified FUGW (Dr. David Baltimore, California Institute of Technology, Pasadena, CA, and Dr. Pavel Osten, Max-Planck Institute, Heidelberg, Germany) to generate Lenti-shCatB. A construct expressing a scrambled shRNA was used as a control (Lenti-shSCR). To overexpress CatB, the EGFP expression cassette in FUGW was replaced with mouse CatB cDNA (MGC-6211, ATCC, Manassas, VA) or nothing to generate Lenti-CatB or Lenti-control. Lentiviral vectors were generated, purified, and titered as described (Chen et al., 2005) . Briefly, recombinant lentivirus was generated by cotransfecting the transfer vector with two helper plasmids, delta8.9 (packaging vector) and VSV-G (envelope vector), into 293T cells (American Type Culture Collection) and purified by ultracentrifugation. Viral titers were determined by p24 ELISA (Perkin Elmer, Boston, MA) at the UCSF Laboratory of Clinical Virology. After 5 days in culture, cortical neuronal cultures from hAPP pups were infected with Lenti-shCatB to inhibit CatB activity or with Lenti-CatB to elevate CatB activity. Equal amounts of Lenti-shSCR and Lenti-control were used as controls for Lenti-shCatB and Lenti-CatB, respectively. Four days later, supernatants were collected for Ab1-x and Ab1-42 ELISA (Johnson-Wood et al., 1997) , and cell lysates were harvested for assays of CatB activity (EMD Biosciences, San Diego, CA) and protein levels (BCA, Pierce Biotechnology, Rockford, IL).
To overexpress hAPP, an adenoviral vector encoding human APP695 cDNA under control of the cytomegalovirus promoter was used to infect neurons cultured from CatB +/+ and CatB 2/2 pups after 5 days in culture. The neurons were initially cultured in B27 and switched to N2 medium by half change on days 2, 3, and 4. On day 7, supernatants and cells were harvested for Ab ELISA, CatB activity assay, and BCA protein assays.
Stereotaxic Injection of Lentiviral Vectors
The recombinant lentiviral vectors (3 ml, an equivalent of p24 w150-200 ng of lentiviral particles) were stereotaxically injected into the hippocampus of hAPP mice at the following coordinates: anterior posterior, 22.2; medial lateral, 61.8, dorsal ventral, 21.9. To confirm region-specific overexpression of CatB and NEP in hAPP mice, 3 weeks after injection, mice were flush perfused transcardially with saline, and brain tissues were rapidly removed. Both hemibrains were postfixed in 4% paraformaldehyde for immunostaining. The contralateral side was marked with a notch before sectioning. The transduction of enzymatically active CatB was confirmed in a cohort of CatB +/2 mice 3 weeks after the injection. The hippocampal lysates were prepared by homogenizing in Cytobuster (Innozyme Cathepsin B Activity Assay Kit, EMD Biosciences) in the absence of protease inhibitors. CatB activity in the ipsilateral hippocampus was compared with that of the contralateral side.
The injection-induced effects on Ab deposition were expressed as the ratio of the percent area of 3D6-immunoreactive or thioflavin S-positive material on the injected versus the noninjected side. Quantitative analyses were performed with ImageJ software (NIH Image). Three to five coronal sections were analyzed per mouse, and the average ratios were used to calculate group means.
Quantification of Ab
Snap-frozen hippocampi were homogenized in guanidine buffer, and human Ab peptides were quantitated by ELISA as described (Johnson-Wood et al., 1997) . Human Ab in the supernatants of primary cortical neurons was also measured by ELISA. The Ab1-42 ELISA detects only Ab1-42, and the Ab1-x ELISA detects Ab1-40, Ab1-42, and Ab1-43, as well as C-terminally truncated forms of Ab containing amino acids 1-28.
Ab Preparations and Electron Microscopy
Ab1-42 and Ab1-40 were from rPeptide (Athens, GA). Ab powders lyophilized with hexafluoroisopropanol were reconstituted in dry dimethylsulfoxide (Sigma) at a concentration of 5 mM. Aggregated Ab1-42 was prepared based on protocols developed in previous studies (Dahlgren et al., 2002; Lambert et al., 1998) . For nonfibrillar Ab assemblies, DMEM/F-12 was added to achieve a final peptide concentration of 100 mM and incubated at 4 C for 24 hr. For fibrillar conditions, 10 mM HCl was added to achieve a final peptide concentration of 100 mM and incubated for 24 hr at 37 C. For nonaggregated conditions (fresh Ab), the 5 mM Ab in Me 2 SO 4 was diluted directly into cell culture medium. For Ab1-40 aggregation, Ab1-40 was reconstituted in H 2 O at a concentration of 5 mg/ml and incubated for 1 week at 37 C. Ab1-42 and Ab1-40 samples were characterized by negativestaining electron microscopy (JEOL 1230, Peabody, MA). Samples were prepared with ''matured'' carbon-coated grids and 2% potassium phosphotungstate (pH 6.5), using the drop method (Hamilton et al., 1980) , and examined at 80 KV with a condenser aperture of 200 mm and an objective aperture of 50 mm. Images were obtained with a Gatan Ultrascan USC1000 digital camera (Gatan, Warrendale, PA).
In Vitro Cleavage Assay Different amounts of purified CatB from human liver (Sigma) were preactivated with 4 mM cysteine at room temperature for 5 min in assay buffer (pH 6.0 or 7.0 after adjustment) (Cathepsin B Activity Assay Kit, EMD Biosciences). Then, 20 ng of fresh, protofibrillar, or fibrillar Ab1-42 was added and incubated at 37 C for 120 min. All samples were run in parallel with and without the specific CatB inhibitor CA074. CatB-induced peptidase cleavage of Ab1-42 was detected with mass spectrometry. Briefly, 5 ml of the reaction mixture was applied to an NP-20 normal-phase chip (Ciphergen Biosystems, Fremont, CA), and the spots were washed with water and air dried. Twenty percent a-cyano-4-hydroxycinnamic acid in 50% acetonitrile, 0.5% trifluoroacetic acid (2 3 0.5 ml) was applied, and the chips were allowed to dry. Samples were analyzed in a PBS IIC SELDI-TOF mass spectrometer (Ciphergen) as an average of 160 shots for each spot. The system was calibrated daily with All-in-One peptide standards (Ciphergen) and synthetic Ab1-42.
The products were also analyzed by western blotting on acid-urea gels with an anti-Ab antibody (3D6) as described (DeMattos et al., 2001; Esposito et al., 2004) or on a Tricine SDS-PAGE. Briefly, 10 ml of the reaction mixture was resolved on 16% tricine gels and transferred to nitrocellulose membranes. Membranes were labeled with 21F12 (1:2000, Elan Pharmaceuticals), an antibody specific for Ab1-42, to detect low MW Ab1-42 oligomers. Since 21F12 was unable to detect higher MW assemblies, 3D6 (1:2000, Elan) was also used for immunoblotting. After incubation with an HRP-conjugated sheep anti-mouse IgG (1:2000; Amersham) secondary antibody, blots were developed with an ECL system (Perkin Elmer).
Quantification of CatB Activities and CatB mRNA
CatB activities in N2A cells or in hippocampus of hAPP mice and their littermate controls were quantified with the Innozyme Cathepsin B Activity Assay Kit (EMD Biosciences), according to the manufacturer's instructions. Cells or hippocampi were lysed in lysis buffer in the absence of proteinase inhibitors, preactivated with 4 mM cysteine, and incubated with the synthetic substrate Z-Arg-Arg AMC at 37 C for 30 min. Released free AMC was determined fluorometrically as above. The enzymatic activities inhibited by CA074 were defined as CatB-specific activities. Protein concentrations were measured with the BCA protein assay kit (Pierce) and used to normalize CatB activities.
Expression of CatB was measured by quantitative RT-PCR. Total RNA in N2A cells was isolated with Trizol reagent (Invitrogen). After treatment with RNase-free DNase (Ambion) for 30 min at 37 C, total RNA (60 ng/ml) was reverse transcribed with random hexamers and oligo d(T) primers. The expression of CatB relative to GAPDH was determined with SYBR green dye chemistry and an ABI Prism 7700 sequence detector (Applied Biosystems, Foster City, CA), as recommended by the manufacturer. Primer quality was verified by dissociation curve analysis, the slopes of standard curves, and reactions without RT. The following primers were used: mouse CatB (forward, 5 0 -TGGTTTCAGGTGGAGTCTACA-3 0 ; reverse, 5 0 -TGCACTG GAGAA GGAGATACT-3 0 ) and mouse GAPDH (forward, 5 0 -GGG AAGCCCATCACCATCTT-3 0 ; reverse, 5 0 -GCCTTCTCCATGGTGGT GAA-3 0 ).
Statistical Analysis
Statistical analyses were carried out with Graphpad Prism (San Diego, CA). For quantification of calbindin and plaque load, experimenters were blinded to the genotypes of the mice. Differences among multiple means were evaluated by ANOVA and the TukeyKramer post hoc test. Differences between means were assessed with the unpaired, two-tailed Student's t test or the Mann-Whitney U test. The null hypothesis was rejected at the 0.05 level.
Supplemental Data
The Supplemental Data include six supplemental figures and can be found with this article online at http://www.neuron.org/cgi/content/ full/51/6/703/DC1/.
